Monday, 15th September, 2025
THE HERITAGE ISSUE
Happy Anniversaries! ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
iStent inject ® W is a POWERFUL, PREDICTABLE, PROVEN technology for a safe earlier intervention delaying disease progression
TRULY MICRO INVASIVE1-3
EXCELLENT SAFETY PROFILE5,6
DELAYS DISEASE
PROGRESSION4
Important safety information (ISI) at: www.glaukos.com 1- Samuelson, Thomas W., et al. “Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject® pivotal trial.” American Journal of Ophthalmology 229 (2021): 220-229. 2- Ioannidis, Alexandros S., et al. “Refractive outcomes after trabecular microbypass stents (iStent Inject) with cataract extraction in open-angle glaucoma.” Clinical Ophthalmology (2020): 517-524. 3-Rodriguez-Una, Ignacio, Augusto Azuara-Blanco, and Anthony J. King. “Survey of glaucoma surgical preferences and post-operative care in the United Kingdom.” Clinical & Experimental Ophthalmology 45.3 (2017): 232-240. 4- Gillmann, Kevin, and Dana M. Hornbeak. “Rates of visual field change and functional progression in glaucoma following trabecular microbypass implantation of iStent technologies: a meta-analysis.” BMJ Open Ophthalmology 9.1 (2024): e001575. 5- Ahmed, Iqbal Ike K., et al. “Corneal Endothelial Safety Profile in Minimally Invasive Glaucoma Surgery.”Journal of Cataract & Refractive Surgery(2022): 10-1097. 6- Samuelson, Thomas W., et al. “Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results.” Ophthalmology 126.6 (2019): 811-821.